BELITE BIO (BLTE) CEO gains 10,000 shares from vested RSUs

Rhea-AI Filing Summary

BELITE BIO, INC director and CEO Yu-Hsin Lin reported a compensation-related share vesting. On 04/21/2026, 10,000 ordinary shares were delivered upon vesting of restricted stock units granted on September 15, 2025 after specified performance criteria were met.

Following this non-market transaction, Lin directly holds 182,949 ordinary shares. The event reflects equity-based compensation vesting rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lin Yu-Hsin

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Other	Ordinary Share	10,000	$0.00	--

Holdings After Transaction: Ordinary Share — 182,949 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs vested: 10,000 ordinary shares Shares after transaction: 182,949 ordinary shares Grant date: September 15, 2025 +2 more

5 metrics

RSUs vested 10,000 ordinary shares Performance-based RSUs vesting on 04/21/2026

Shares after transaction 182,949 ordinary shares Direct holdings following RSU vesting

Grant date September 15, 2025 Date RSU award was granted

Vesting date April 21, 2026 Date performance criteria were met and RSUs vested

Transaction code J Other acquisition or disposition (restructuring-type event)

Key Terms

restricted stock units ("RSUs"), performance criteria, vesting, Form 4

4 terms

restricted stock units ("RSUs") financial

"the reporting person was granted an award of restricted stock units ("RSUs") which shall vest"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

performance criteria financial

"RSUs which shall vest upon satisfaction of certain performance criteria"

vesting financial

"resulting in vesting of the RSUs as to 10,000 ordinary shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 regulatory

"reported in a Form 4 insider transaction filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Yu-Hsin

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Share	04/21/2026		J(1)		10,000(1)	A	$0(1)	182,949	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 15, 2025, the reporting person was granted an award of restricted stock units ("RSUs") which shall vest upon satisfaction of certain performance criteria. Such performance criteria was met on 04/21/2026, resulting in vesting of the RSUs as to 10,000 ordinary shares.

	/s/ Yu-Hsin Lin	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BELITE BIO (BLTE) report for Yu-Hsin Lin?

BELITE BIO reported that CEO and director Yu-Hsin Lin received 10,000 ordinary shares through vesting of restricted stock units. These RSUs were granted earlier and vested after performance criteria were satisfied, making this a compensation-related equity delivery, not an open-market trade.

How many BELITE BIO (BLTE) shares did Yu-Hsin Lin receive in this Form 4?

Yu-Hsin Lin received 10,000 ordinary shares. The shares came from performance-based restricted stock units that vested once the required criteria were met, representing additional equity compensation rather than a market purchase or sale at a specific price.

What is Yu-Hsin Lin’s BELITE BIO (BLTE) shareholding after this transaction?

After the RSU vesting, Yu-Hsin Lin directly holds 182,949 ordinary shares. This figure reflects his position following the delivery of 10,000 shares from vested restricted stock units, as reported in the Form 4 filing for this transaction.

Was the BELITE BIO (BLTE) Form 4 transaction a market buy or sell?

The Form 4 transaction was not a market buy or sell. It reflects an “other” type transaction where restricted stock units vested upon meeting performance criteria, resulting in delivery of 10,000 ordinary shares as equity compensation to Yu-Hsin Lin.

What performance-based award triggered Yu-Hsin Lin’s new BELITE BIO (BLTE) shares?

A restricted stock unit award granted on September 15, 2025 triggered the new shares. The RSUs vested when certain performance criteria were met on April 21, 2026, resulting in 10,000 ordinary shares being delivered to Yu-Hsin Lin under the award’s terms.